UCB Exercises Tozadenant Option But Asks Biotie To Move It To Phase III
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotie Therapies gets $20 million as UCB exercises its option on the investigational Parkinson's disease therapy tozadenant and asks the Finnish biotech to continue its clinical development of the product into Phase III.